

Sifat Sharmin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1098325/publications.pdf>

Version: 2024-02-01

25
papers

773
citations

759233

12
h-index

642732

23
g-index

25
all docs

25
docs citations

25
times ranked

1054
citing authors

#	ARTICLE	IF	CITATIONS
1	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 307-316.	10.2	219
2	Orthostatic Hypotension and Falls in Older Adults: A Systematic Review and Meta-analysis. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 589-597.e5.	2.5	101
3	The emergence of dengue in Bangladesh: epidemiology, challenges and future disease risk. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2015, 109, 619-627.	1.8	73
4	Interaction of Mean Temperature and Daily Fluctuation Influences Dengue Incidence in Dhaka, Bangladesh. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003901.	3.0	64
5	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.	1.1	54
6	Geostatistical mapping of the seasonal spread of under-reported dengue cases in Bangladesh. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006947.	3.0	36
7	Orthostatic hypotension and cognition in older adults: A systematic review and meta-analysis. <i>Experimental Gerontology</i> , 2019, 120, 40-49.	2.8	35
8	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413.	7.6	32
9	Profile: The Chakaria Health and Demographic Surveillance System. <i>International Journal of Epidemiology</i> , 2012, 41, 667-675.	1.9	26
10	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1398.	9.0	21
11	Comparing indigenous mortality across urban, rural and very remote areas: a systematic review and meta-analysis. <i>International Health</i> , 2018, 10, 219-227.	2.0	16
12	Trajectories of Mini-Mental State Examination Scores over the Lifespan in General Populations: A Systematic Review and Meta-Regression Analysis. <i>Clinical Gerontologist</i> , 2022, 45, 467-476.	2.2	16
13	A Bayesian approach for estimating under-reported dengue incidence with a focus on non-linear associations between climate and dengue in Dhaka, Bangladesh. <i>Statistical Methods in Medical Research</i> , 2018, 27, 991-1000.	1.5	15
14	The histopathological staging of tau, but not amyloid, corresponds to antemortem cognitive status, dementia stage, functional abilities and neuropsychiatric symptoms. <i>International Journal of Neuroscience</i> , 2021, 131, 800-809.	1.6	14
15	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 755-766.	3.0	11
16	The effectiveness of natalizumab vs fingolimod—A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103012.	2.0	8
17	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.	5.9	8
18	Multiple Sclerosis Relapses Following Cessation of Fingolimod. <i>Clinical Drug Investigation</i> , 2022, 42, 355-364.	2.2	8

#	ARTICLE	IF	CITATIONS
19	Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009â€“2018. CNS Drugs, 2021, 35, 1097-1106.	5.9	7
20	Modelling of Infectious Diseases for Providing Signal of Epidemics: A Measles Case Study in Bangladesh. Journal of Health, Population and Nutrition, 2012, 29, 567-73.	2.0	3
21	Predicting allâ€cause unplanned readmission within 30 days of discharge using electronic medical record data: A multiâ€centre study. International Journal of Clinical Practice, 2021, 75, e14306.	1.7	3
22	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Multiple Sclerosis Journal, 2022, , 135245852210845.	3.0	2
23	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 2022, , .	3.3	1
24	006â€...Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models. , 2021, , .		0
25	009â€...Predicting infection risk in multiple sclerosis patients treated with ocrelizumab: a retrospective cohort study. , 2021, , .		0